期刊
INFLAMMATORY BOWEL DISEASES
卷 20, 期 3, 页码 564-575出版社
OXFORD UNIV PRESS INC
DOI: 10.1097/01.MIB.0000437986.00190.71
关键词
disease activity; outcome measures; indices; histology; ulcerative colitis
资金
- Millennium Pharmaceuticals
- Merck
- Tillotts Pharma AG
- Abbott Labs
- Novartis Pharmaceuticals
- Centocor Inc.
- Elan/Biogen
- UCB Pharma
- Bristol-Myers Squibb
- Genentech
- ActoGenix
- Wyeth Pharmaceuticals Inc.
- Janssen-Ortho
- Teva Pharmaceuticals
- Celgene
- Astra Zeneca
- Serono
- Unity Pharmaceuticals
- Albireo Pharma
- Given Imaging Inc.
- Salix Pharmaceuticals
- Novonordisk
- GSK
- Prometheus Therapeutics
- Diagnostics
- Athersys
- Axcan
- Gilead
- Pfizer
- Shire
- Wyeth
- Zealand Pharma
- Zyngenia
- GiCare Pharma Inc. Sigmoid Pharma
- Abbott
- ActoGeniX NV
- AGI Therapeutics Inc
- Alba Therapeutics Corp, Albireo
- Alfa Wasserman
- Amgen
- AM-Pharma BV
- Anaphore
- Astellas
- Athersys Inc
- Atlantic Healthcare Ltd
- Aptalis
- BioBalance Corp
- Boehringer-Ingelheim
- Celek Pharmaceuticals
- Cellerix SL
- Cerimon Pharmaceuticals
- ChemoCentryx
- CoMentis
- Cosmo Technologies
- Coronado Biosciences
- Cytokine Pharmasciences
- Eagle Pharmaceuticals
- EnGene Inc
- Eli Lilly
- Enteromedics
- Exagen Diagnostics Inc
- Ferring Pharmaceuticals
- Flexio Therapeutics Inc
- Funxional Therapeutics Ltd
- Genzyme Corp
- Gilead Sciences
- Given Imaging
- Human Genome Sciences
- Ironwood Pharmaceuticals
- KaloBios Pharmaceuticals
- Lexicon Pharmaceuticals
- Lycera Corp
- Meda Pharmaceuticals
- Merck Research Laboratories
- Merck Serono
- Millenium Pharmaceuticals
- Nisshin Kyorin Pharmaceuticals
- Novo Nordisk
- NPS Pharmaceuticals
- Optimer Pharmaceuticals
- Orexigen Therapeutics Inc
- PDL Biopharma
- Procter and Gamble
- Prometheus Laboratories
- ProtAb Ltd
- Purgenesis Technologies Inc
- Relypsa Inc
- Roche
- Salient Pharmaceuticals
- Santarus
- Schering Plough
- Shire Pharmaceuticals
- Sigmoid Pharma Ltd
- Sirtris Pharmaceuticals
- SLA Pharma UK Ltd
- Targacept
- Therakos
- TxCell SA
- Viamet Pharmaceuticals
- Vascular Biogenics Ltd
- Warner Chilcott UK Ltd
- Janssen
- Milennium Pharmaceuticals
- Novartis
- Sigmoid Pharma
- Robarts Clinical Trials
- Santarus Inc.
- Prometheus labs
Background: Ulcerative colitis (UC) is an idiopathic inflammatory disorder. Currently, the main goals of treatment are to induce and maintain clinical and/or endoscopic remission. However, evidence indicates that persistent disease activity on colonic biopsies in the setting of clinical or endoscopic remission is an independent predictor of poor outcomes. A number of previous studies have proposed histologic indices for use in specific trials of UC. The aim of this study was to systematically review the existing histological indices for UC and assess their potential use in both patient management and clinical trials. Methods: We performed a systematic review of histological indices evaluating disease activity in UC. MEDLINE (Ovid), EMBASE (Ovid), PubMed, the Cochrane Library (CENTRAL), and Digestive Diseases Week (DDW) abstracts of randomized and/or controlled trials clinical trials were searched from inception to February 2013 for applicable studies. Data from these studies were reviewed and analyzed. Results: After systematically applying inclusion criteria, we identified 108 scientific articles including 88 clinical studies and 21 related clinical reviews. Eighteen indices of histological activity in UC were identified and reviewed. Conclusions: Although multiple histological scoring indices for assessment of UC disease activity currently exist, none of these instruments were developed using a formal validation process and their operating properties remain poorly understood. Future studies are needed to address this deficiency.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据